Clinical Research Directory
Browse clinical research sites, groups, and studies.
Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate
Sponsor: University Medical Center Groningen
Summary
The goal of this clinical trial is to investigate the uptake characteristics of \[18F\]CETO in adrenal tissue in patients with two different subtypes of primary aldosteronism. The main questions it aims to answer are: * What are the uptake characteristics of \[18F\]CETO in adrenal tissue in patients with primary aldosteronism? * What is the concordance between the adrenal vein sampling and the \[18F\]CETO PET/CT scan results? * What is the effect of adrenal perfusion on \[18F\]CETO uptake in the adrenal glands? Researchers will compare the results of the adrenal vein sampling to a \[18F\]CETO PET/CT scan to see if the PET/CT can accurately identify the subtypes of primary aldosteronism. Participants will: * Take dexamethasone three days prior to the scan * Undergo a \[18F\]CETO PET/CT * Report burden of pre-treatment and PET/CT scan
Official title: Para-chloro-2-[18F]Fluoroethyl-etomidate ([18F]CETO) as a New PET-tracer for Subtyping in Patients With Primary Aldosteronism - a Pilot Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2024-11-06
Completion Date
2027-05
Last Updated
2025-01-27
Healthy Volunteers
No
Conditions
Interventions
[18F]CETO tracer
PET/CT with para-chloro-2-\[18F\]fluoroethyl-etomidate (\[18F\]CETO) has a high specificity for the steroidogenic enzymes CYP11B1 and CYP11B2, present in the adrenal cortex, and has more favourable tracer characteristics compared to \[11C\]metomidate. Results obtained with this novel tracer seem promising, but its potential value in the subtyping of PA needs to be further established.
Dexamethasone oral
Pre-treatment of dexamethasone prior to 18F CETO PET/CT scan
Adrenal vein sampling
Adrenl vein sampling
Locations (1)
University Medical Center Groningen
Groningen, Provincie Groningen, Netherlands